Table 1.
Demographic data for all study participants (n=34).
| n (%) | |
|---|---|
| Age (years, std) | 53.3 ± 11.9 |
| Female | 30 (88) |
| Type of MS | |
| Relapsing Remitting | 18 (53) |
| Secondary Progressive | 7 (20) |
| Primary Progressive | 5 (15) |
| Unknown | 4 (12) |
| Time since first symptom (years, std) | 19.4 ± 12.7 |
| Time since diagnosis (years, std) | 12.9 ± 9.9 |
| Using Disease Modifying Therapy (DMT)a | |
| Yes | 20 (59) |
| No | 13 (38) |
| Missing data | 1 (3) |
| Using medication for stress, depression, or anxietyb | |
| Yes | 20 (59) |
| No | 13 (38) |
| Missing data | 1 (3) |
| Education | |
| HS Diploma | 15 (44) |
| College Grad | 19 (56) |
| Disabilityc | |
| None/minimal | 1 (3) |
| Mild | 11 (31) |
| Moderate | 8 (24) |
| Some support needed | 8 (24) |
| Walker or two handed crutch | 2 (6) |
| Unable to walk | 3 (9) |
| Missing data | 1 (3) |
| Have health insurance | |
| Yes | 23 (67) |
| No | 10 (30) |
| Missing data | 1 (3) |
| Ethnicity | |
| White | 34 (100) |
| Other | 0 |
a
DMTs used by participants included: glatiramer acetate, interferon-1b, interferon-1a, natalizumab, and fingolimod.
b
Medications for stress, anxiety, or depression used by participants included: alprazolam, aripiprazole, bupropion, citalopram, clonazepam, duloxetine, escitalopram, fluoxetine, lorazepam, sertraline, venlafaxine
c
Disability status was generated by a self-report scale previously shown to correlate with Expanded Disability Severity Scale scores (r=0.85) (Shinto et al., 2006).